BRIEF-Carisma And Moderna Expand Collaboration To Develop Two In Vivo CAR-M Therapies For Autoimmune Diseases

Reuters09-10

Sept 10 (Reuters) - Carisma Therapeutics Inc :

* CARISMA AND MODERNA EXPAND COLLABORATION TO DEVELOP TWO IN VIVO CAR-M THERAPIES FOR AUTOIMMUNE DISEASES

* CARISMA THERAPEUTICS INC - MODERNA NOMINATES TWO AUTOIMMUNE DISEASE TARGETS UNDER COLLABORATION

* CARISMA THERAPEUTICS INC - TO HANDLE DISCOVERY, MODERNA TO LEAD CLINICAL DEVELOPMENT

* CARISMA THERAPEUTICS INC - ELIGIBLE FOR MILESTONES AND ROYALTY PAYMENTS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466543928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466543928","market":"us","top_or_hot":-1,"title":"BRIEF-Carisma And Moderna Expand Collaboration To Develop Two In Vivo CAR-M Therapies For Autoimmune Diseases","media":"Reuters","content":"<html><body><p>Sept 10 (Reuters) - <a href=\"https://laohu8.com/S/CARM\">Carisma Therapeutics</a> Inc   :</p><p>   * CARISMA AND MODERNA EXPAND COLLABORATION TO DEVELOP TWO IN VIVO CAR-M THERAPIES FOR AUTOIMMUNE DISEASES</p><p>   * CARISMA THERAPEUTICS INC - MODERNA NOMINATES TWO AUTOIMMUNE DISEASE TARGETS UNDER COLLABORATION</p><p>   * CARISMA THERAPEUTICS INC - TO HANDLE DISCOVERY, MODERNA TO LEAD CLINICAL DEVELOPMENT</p><p>   * CARISMA THERAPEUTICS INC - ELIGIBLE FOR MILESTONES AND ROYALTY PAYMENTS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Carisma And Moderna Expand Collaboration To Develop Two In Vivo CAR-M Therapies For Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Carisma And Moderna Expand Collaboration To Develop Two In Vivo CAR-M Therapies For Autoimmune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 10 (Reuters) - Carisma Therapeutics Inc   :   * CARISMA AND MODERNA EXPAND COLLABORATION TO DEVELOP TWO IN VIVO CAR-M THERAPIES FOR AUTOIMMUNE DISEASES   * CARISMA THERAPEUTICS INC - MODERNA ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2466543928","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466543928","pubTimestamp":1725968466,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 10  - Carisma Therapeutics Inc   :   * CARISMA AND MODERNA EXPAND COLLABORATION TO DEVELOP TWO IN VIVO CAR-M THERAPIES FOR AUTOIMMUNE DISEASES   * CARISMA THERAPEUTICS INC - MODERNA NOMINATES TWO AUTOIMMUNE DISEASE TARGETS UNDER COLLABORATION   * CARISMA THERAPEUTICS INC - TO HANDLE DISCOVERY, MODERNA TO LEAD CLINICAL DEVELOPMENT   * CARISMA THERAPEUTICS INC - ELIGIBLE FOR MILESTONES AND ROYALTY PAYMENTSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4588":"碎股","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","CARM":"Carisma Therapeutics","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","MRNA":"Moderna, Inc.","BK4501":"段永平概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","CAR":"安飞士"},"translate_title":"简介-Carisma和Moderna扩大合作开发两种治疗自身免疫性疾病的体内CAR-M疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1,"CARM":0.9,"MRNA":0.9},"content_text":"Sept 10 (Reuters) - Carisma Therapeutics Inc   :   * CARISMA AND MODERNA EXPAND COLLABORATION TO DEVELOP TWO IN VIVO CAR-M THERAPIES FOR AUTOIMMUNE DISEASES   * CARISMA THERAPEUTICS INC - MODERNA NOMINATES TWO AUTOIMMUNE DISEASE TARGETS UNDER COLLABORATION   * CARISMA THERAPEUTICS INC - TO HANDLE DISCOVERY, MODERNA TO LEAD CLINICAL DEVELOPMENT   * CARISMA THERAPEUTICS INC - ELIGIBLE FOR MILESTONES AND ROYALTY PAYMENTSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466543928"}